{"id":"NCT00118703","sponsor":"GlaxoSmithKline","briefTitle":"Once-Daily Investigational Nasal Spray In Adults And Adolescents With Vasomotor Rhinitis","officialTitle":"A 4 Week Randomized, Double Blind, Placebo Controlled Study of GW685698X Aq Nasal Spray 100mcg QD in Adults and Adolescents With Vasomotor Rhinitis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2005-07-01","primaryCompletion":"2006-02-01","completion":"2006-02-09","firstPosted":"2005-07-12","resultsPosted":"2017-05-02","lastUpdate":"2017-08-21"},"enrollment":350,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Vasomotor Rhinitis","Rhinitis, Vasomotor"],"interventions":[{"type":"DRUG","name":"GW685698X","otherNames":[]}],"arms":[],"summary":"The primary objective of this study is to compare the efficacy and safety of GW685698X 100mcg once daily (QD) aqueous nasal spray with vehicle placebo nasal spray in adult and adolescent subjects (12 years of age and older) with vasomotor rhinitis (VMR).","primaryOutcome":{"measure":"Mean Change From Baseline in Daily Reflective Total Nasal Symptom Scores (rTNSS)","timeFrame":"Baseline and up to Week 4","effectByArm":[{"arm":"Placebo","deltaMin":-2.11,"sd":0.15},{"arm":"Fluticasone Furoate 110 Âµg QD","deltaMin":-2.01,"sd":0.15}],"pValues":[{"comp":"OG000 vs OG001","p":"0.604"}]},"eligibility":{"minAge":"12 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":3},"locations":{"siteCount":59,"countries":["United States","Canada","Czechia","Germany","Norway","Puerto Rico","Romania"]},"refs":{"pmids":[],"seeAlso":["https://www.clinicalstudydatarequest.com"]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":173},"commonTop":["Headache","Nasopharyngitis","Epistaxis","Pharyngolaryngeal pain","Back pain"]}}